Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.

Objective: Shufeng Jiedu capsule (SFJDC) is a well-known Chinese patent drug that is recommended as a basic prescription and applied widely in the clinical treatment of COVID-19. However, the exact molecular mechanism of SFJDC remains unclear. The present study aims to determine the potential pharmacological mechanisms of SFJDC in the treatment of COVID-19 based on network pharmacology.

WITHDRAWN: Application of Echocardiographic Information Technology in the Research of Infective Endocarditis and Its Neurological Complications.

This article has been withdrawn at the request of the Editor-in-Chief. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.

[Effects of adenosine a1 receptors on l-name induced the second window of cardioprotection in isolated/perfused rat hearts].

Aims: The aim of this study is to demonstrate whether adenosine A1 receptors may be a mediator of L-NAME induced the second window of cardioprotection.

Materials And Methods: Three groups of Sprague-Dawley rats (control group = 10, L-NAME group = 10 and DPCPX group = 10) were studied in an isolated/perfused heart model. After excision of the hearts, the hearts have been stabilized in the KH solution for 15 minutes (S15), followed by cardiac ischemic for 60 minutes and the reperfusion during 120 minutes but subdivided into three periods: R1, R60 and R120.